108例骨髓增殖性肿瘤患者基因突变及临床特征分析
该研究采用二代测序127基因 panel 检测108例初诊BCR-ABL阴性MPN患者(ET 55例、PV 24例、PMF 29例)的基因突变,分析突变与临床特征的关系。结果显示92.59%患者检出突变,69.56%驱动基因突变患者携带至少1种附加突变,24.1%检出高危突变,PMF附加基因平均突变数更高且ASXL1突变频率更高。
要点
- 100例(92.59%)患者检出32种基因共211个突变,人均(1.96±1.32)个。
- PMF附加基因平均突变数(1.69±1.39)高于ET(0.67±0.70)及PV(0.87±1.22),P=0.001。
- ASXL1突变PMF患者PLT和HGB水平更低(P=0.029、0.019)。
核心结论
- 69.56%的MPN患者携带至少1种附加基因突变,24.1%检出高危基因突变(HMR),各亚组有不同的基因突变模式。
- PMF患者附加基因平均突变数目更多,ASXL1突变频率更高,ASXL1突变的PMF患者PLT和HGB水平更低。
研究设计与样本
- 应用二代测序127基因 panel 检测108例初诊BCR-ABL阴性MPN患者[ET 55例、PV 24例、PMF 29例]的基因突变,并分析基因突变与临床特征的关系。
主要发现
- 100例(92.59%)患者检出32种基因共211个突变,人均检出(1.96±1.32)个突变。
- 85.19%(92/108)患者检出驱动基因(JAK2、CALR、MPL)突变,其中69.56%(64/92)至少检出1种附加基因突变。
- 按突变频率由高到低依次为激活信号通路基因(42.2%,89/211)、DNA甲基化基因(17.6%,36/211)、染色质修饰基因(16.1%,34/211)。
- PMF附加基因平均突变数目高于ET及PV患者(1.69±1.39、0.67±0.70、0.87±1.22,χ²=13.445,P=0.001)。
- 检出≥3个突变基因患者MPN10评分(P=0.006)、骨髓纤维化程度(P=0.015)均较检出<3个突变基因患者高,且HGB水平更低(P=0.002)。
关键数值与推荐
- 驱动基因(JAK2、CALR、MPL)突变检出率85.19%(92/108)。
- 附加基因突变在驱动基因突变患者中的检出率69.56%(64/92)。
- 高危基因突变(HMR)检出率24.1%(26/108)。
- PMF患者ASXL1突变频率37.9%对PV患者4.2%(P=0.005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the genetic mutations and clinical features of the subtypes of classical BCR-ABL-negative myeloproliferative neoplasm (MPN) . Methods: Mutations of 108 newly diagnosed BCR-ABL-negative MPN patients [including 55 patients with essential thrombocytopenia (ET) , 24 with polycythemia vera (PV) , and 29 with primary myelofibrosis (PMF) ] were identified using next-generation sequencing with 127-gene panel, and the relationship between gene mutations and clinical features were analyzed. Results: Total 211 mutations in 32 genes were detected in 100 MPN patients (92.59% ) , per capita carried (1.96±1.32) mutations. 85.19% (92/108) patients carried the driver gene (JAK2, CALR, MPL) mutations, 69.56% (64/92) of these patients carried at least 1 additional gene mutation. In descending order of mutation frequency, the highest frequency was for activation signaling pathway genes (42.2% , 89/211) , methylation genes (17.6% , 36/211) , and chromatin-modified genes (16.1% , 34/211) . There was a significant difference in the number of mutations in the activation signaling pathway genes, epigenetic regulatory genes, spliceosomes, and RNA metabolism genes among the three MPN subgroups. The average number of additional mutations in PMF patients was higher than that in ET and PV patients (1.69±1.39, 0.67±0.70, 0.87±1.22, χ(2)=13.445, P=0.001) . MPN-SAF-TSS (MPN 10 score) (P=0.006) and myelofibrosis level (P=0.015) in patients with ≥ 3 mutant genes were higher and the HGB level (P=0.002) was lower than in those with<3 mutations. Twenty-six patients (24.1% ) carried high-risk mutation (HMR) , and patients with HMR had lower PLT (P=0.017) , HGB levels (P<0.001) , and higher myelofibrosis level (P=0.010) and MPN10 score (P<0.001) . The frequency of ASXL1 mutations was higher in PMF than in PV patients (34.5% vs. 4.2% , P=0.005) . PMF patients with ASXL1 had lower levels of PLT and HGB (P=0.029 and 0.019) . Conclusion: 69.56% of MPN patients carry at least one additional mutation, and 24.1% patients had HMR. Each subgroup had different mutation patterns. PMF patients had a higher average number of additional gene mutations, especially a higher frequency of ASXL1 mutation; PLT and HGB levels were lower in ASXL1 mutation PMF patients. 目的: 分析经典型BCR-ABL阴性骨髓增殖性肿瘤(MPN)的基因突变及临床特征。 方法: 应用二代测序方法检测108例初诊BCR-ABL阴性MPN患者[原发性血小板增多症(ET)55例,真性红细胞增多症(PV)24例,原发性骨髓纤维化(PMF)29例]与疾病相关的127个基因突变情况,并分析基因突变与临床特征间的关系。 结果: 108例MPN患者中,100例(92.59%)检出32种基因共211个突变,人均检出(1.96±1.32)个突变。85.19%(92/108)的患者检出驱动基因(JAK2、CALR、MPL)突变,其中69.56%(64/92)的患者至少检出1种附加基因突变。按突变频率由高到低依次为激活信号通路基因(42.2%,89/211)、DNA甲基化基因(17.6%,36/211)、染色质修饰基因(16.1%,34/211)。PV、ET、PMF三组间激活信号通路基因、表观遗传调节基因、剪接体和RNA代谢基因突变个数差异均有统计学意义,PMF附加基因平均突变数目高于ET及PV患者(1.69±1.39、0.67±0.70、0.87±1.22,χ(2)=13.445,P=0.001)。检出≥3个突变基因患者MPN总症状评估量表(MPN 10评分)(P=0.006)、骨髓纤维化程度(P=0.015)均较检出<3个突变基因患者高,且HGB水平更低(P=0.002);26例(24.1%)患者检出高危基因突变(HMR),HMR突变的患者具有更低的PLT(P=0.017)和HGB水平(P<0.001),更高的骨髓纤维化程度(P=0.010)、MPN10评分(P<0.001)。PMF患者ASXL1突变频率高于PV患者(37.9%对4.2%,P=0.005),ASXL1突变的PMF患者具有更低的PLT和HGB水平(P=0.029、0.019)。 结论: 近七成MPN患者检出至少1种附加基因突变,24.1%检出HMR突变,各亚组有不同的基因突变模式;PMF患者附加基因平均突变数目更多,ASXL1突变频率更高。ASXL1突变的PMF患者PLT和HGB水平更低。.
引用
- Tan YX, Xu N, Huang JX, et al. [Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32810965. doi:10.3760/cma.j.issn.0253-2727.2020.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。